<SEC-DOCUMENT>0001193125-22-146350.txt : 20220510
<SEC-HEADER>0001193125-22-146350.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510162932
ACCESSION NUMBER:		0001193125-22-146350
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20220509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		22910173

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d259881d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20220509" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-05-09_to_2022-05-09">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-05-09_to_2022-05-09">0001055726</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ino-20220509.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-05-09_to_2022-05-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-09</xbrli:startDate> <xbrli:endDate>2022-05-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-05-09_to_2022-05-09">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt:datemonthdayyearen">May 9, 2022</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2022-05-09_to_2022-05-09">Inovio Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-05-09_to_2022-05-09">001-14888</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-05-09_to_2022-05-09">33-0969592</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer<br /></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-05-09_to_2022-05-09">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2022-05-09_to_2022-05-09">Suite 110</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-05-09_to_2022-05-09">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-05-09_to_2022-05-09">PA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-05-09_to_2022-05-09">19462</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, including zip code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-05-09_to_2022-05-09">(267)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-05-09_to_2022-05-09">440-4200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-05-09_to_2022-05-09">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-05-09_to_2022-05-09">INO</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-05-09_to_2022-05-09" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;10, 2022, Inovio Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold">Company</span>&#8221;) issued a press release announcing its financial results for the three months ended March&#160;31, 2022. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2 of Form <span style="white-space:nowrap">8-K,</span> the information in this Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold">Securities Act</span>&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(b)&#160;&#160;&#160;&#160;Resignation of J. Joseph Kim as President, Chief Executive Officer and Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;9, 2022, J. Joseph Kim, President and Chief Executive Officer of the Company, resigned from those positions and also resigned as a member of the Company&#8217;s Board of Directors (the &#8220;<span style="font-weight:bold">Board</span>&#8221;), in each case effective upon the filing of the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended March&#160;31, 2022, which is expected to occur on May&#160;10, 2022 (such filing date, the &#8220;<span style="font-weight:bold">Separation Date</span>&#8221;). Dr.&#160;Kim will no longer stand for <span style="white-space:nowrap">re-election</span> at the Company&#8217;s 2022 annual meeting of stockholders to be held on May&#160;16, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(c)(e)&#160;&#160;&#160;&#160;Appointment of Jacqueline E. Shea as President and Chief Executive Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;10, 2022, the Board appointed Dr.&#160;Jacqueline Shea, currently the Company&#8217;s Chief Operating Officer, to serve as the Company&#8217;s President and Chief Executive Officer, effective upon the effectiveness of Dr.&#160;Kim&#8217;s resignation from those roles. Biographical information about Dr.&#160;Shea is contained in the Company&#8217;s definitive proxy statement for its 2022 annual meeting of stockholders filed with the Securities and Exchange Commission on March&#160;25, 2022 and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no related party transactions between Dr.&#160;Shea and the Company that would require disclosure under Item 404(a) of Regulation <span style="white-space:nowrap">S-K,</span> and there is no family relationship between Dr.&#160;Shea and any of the Company&#8217;s directors or other executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Dr.&#160;Shea&#8217;s appointment as President and Chief Executive Officer, on May&#160;10, 2022, the Board approved, at the recommendation of the Compensation Committee of the Board, an increase in her base salary from $495,000 to $700,000, a <span style="white-space:nowrap">one-time</span> promotion bonus of $100,000 and an increase in her target bonus opportunity from 50% of her current annual base salary to 60% of her increased base salary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on May&#160;10, 2022, the Board approved the grant to Dr.&#160;Shea of equity awards as follows: (a)&#160;a stock option to purchase 309,400 shares, which will vest in four equal installments, with 25% vesting immediately on the grant date and 25% vesting on each anniversary of the grant date thereafter, and (b)&#160;a restricted stock unit for 198,000 shares, which will vest over three years in three equal installments beginning on the first anniversary of the grant date, subject in each case to Dr.&#160;Shea&#8217;s continued service through the applicable vesting date. The stock option grant will have an exercise price equal to the closing price of the Company&#8217;s common stock on the grant date. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each award described above is subject to the terms and conditions of the award agreements pursuant to which they are granted. Dr.&#160;Shea will remain eligible for additional future equity awards as may be determined by the Board, or a committee thereof, in accordance with the Company&#8217;s equity incentive plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(e)&#160;&#160;&#160;&#160;Separation Agreement with J. Joseph Kim </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;10, 2022, Dr.&#160;Kim and the Company entered into a Separation Agreement (the &#8220;<span style="font-weight:bold">Separation Agreement</span>&#8221;) that is materially consistent with, but supersedes, Dr.&#160;Kim&#8217;s employment agreement with the Company, which was filed as Exhibit&#160;10.19 to the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021 and filed with the Securities and Exchange Commission on March&#160;1, 2022. The Separation Agreement provides that Dr.&#160;Kim will receive, subject to him executing a general release of claims in favor of the Company and not revoking the agreement within the period provided by law to do so (the end of such period, the &#8220;<span style="font-weight:bold">Effective Date</span>&#8221;), the following separation payments and benefits: (i)&#160;cash severance of $1,491,074, representing 24&#160;months of his base salary in effect as of the Separation Date, subject to standard deductions and withholdings, payable in a lump sum within 10 days after November&#160;11, 2022; (ii)&#160;additional cash severance of $939,074, subject to standard deductions and withholdings, payable in a lump sum within 10&#160;days after November&#160;11, 2022; (iii)&#160;a COBRA subsidy payment of $93,913.70, paid in installments over the <span style="white-space:nowrap">24-month</span> period following the Separation Date, provided that the first payment will be made within 10&#160;days after November&#160;11, 2022, which will be inclusive of installments otherwise payable prior to that date. The COBRA subsidy payment equals the gross amount of 24&#160;months of payments for premiums under Company&#8217;s health plans for Dr.&#160;Kim and his dependents, grossed up by 45% to offset the payroll taxes and withholdings to be deducted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the equity award agreements for Dr.&#160;Kim&#8217;s outstanding RSUs, as of the Separation Date, the RSUs will become fully vested. As soon as practicable, but no later than June&#160;9, 2022, <span style="white-space:nowrap">one-half</span> of the RSUs will be settled in shares of Company&#8217;s common stock, and <span style="white-space:nowrap">one-half</span> will be settled in cash, based on the fair market value of the Company&#8217;s common stock on the date of settlement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Separation Agreement, the Company has agreed to retain Dr.&#160;Kim as a <span style="white-space:nowrap">non-employee</span> advisor to the Company through May&#160;10, 2025 (the &#8220;<span style="font-weight:bold">Advisory Period</span>&#8221;). Dr.&#160;Kim has agreed to provide services for up to five hours per week for the first six months of the Advisory Period, with a de minimis time commitment thereafter. In exchange for the advisory services, the Company has agreed to pay Dr.&#160;Kim a $15,000 monthly retainer for the first six months of the Advisory Period, then a $5,000 monthly retainer for the second six months of the Advisory Period and a $25,000 annual retainer for the last two years of the Advisory Period. Dr.&#160;Kim&#8217;s outstanding stock options will continue to vest during the Advisory Period, and the Company has agreed to extend the exercise period of Dr.&#160;Kim&#8217;s vested stock options so that they remain exercisable until five years after the Separation Date or, if earlier, the original expiration date of the vested options. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the foregoing benefits, for one year from the Separation Date, Dr.&#160;Kim will have continued access to an executive coach at the Company&#8217;s expense. The Company will also reimburse Dr.&#160;Kim for up to $15,000 in legal expenses incurred in connection with the negotiation of the Separation Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ending June&#160;30, 2022. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;10, 2022, the Company issued a press release announcing the management transition. A copy of this press release is furnished herewith as Exhibit 99.2 to this Current Report. The information contained in this Item 7.01 and in the press release furnished as Exhibit 99.2 shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act and is not incorporated by reference into any of the Company&#8217;s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Exhibit<br />Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d259881dex991.htm">Press Release, dated May&#160;10, 2022, &#8220;INOVIO Reports First Quarter 2022 Financial Results and Program Developments.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d259881dex992.htm">Press Release, dated May&#160;10, 2022, &#8220;INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:1%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">INOVIO PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: May&#160;10, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Peter Kies</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d259881dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g259881g0510123631217.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Reports First Quarter 2022 Financial Results </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and Program Developments </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announces prioritization of heterologous booster strategy for <FONT STYLE="white-space:nowrap">COVID-19</FONT>
vaccine candidate <FONT STYLE="white-space:nowrap">INO-4800</FONT> and discontinuation of Phase 3 INNOVATE trial to optimize potential impact on global public health </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reports, with partner Advaccine, positive T cell immune response data with
<FONT STYLE="white-space:nowrap">INO-4800</FONT> as a heterologous booster to an inactivated <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announces change in plans for <FONT STYLE="white-space:nowrap">VGX-3100</FONT> following input from FDA on need
for additional trials for a marketing application for the treatment of <FONT STYLE="white-space:nowrap">HPV-associated</FONT> cervical high-grade squamous intraepithelial lesions </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announces appointment of Jacqueline Shea, Ph.D. as CEO </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Will hold investor call today at 4:30 PM EDT </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; May&nbsp;10, 2022 &#150; INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to
help protect people from infectious diseases and treat people with cancer and <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases, today reported financial results for the quarter ended March&nbsp;31, 2022 and announced recent program
and corporate developments. INOVIO&#146;s management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update. The live webcast and replay may be accessed by
visiting INOVIO&#146;s website at <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/events-and-presentations/default.aspx</FONT></FONT></U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a separate press release, the Company announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer (CEO). Dr.&nbsp;Shea,
INOVIO&#146;s former Chief Operating Officer, succeeds Dr.&nbsp;J. Joseph Kim in these roles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We believe in the potential of our DNA medicines and
vaccines to combat infectious diseases, cancer and <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases,&#148; said Dr.&nbsp;Jacqueline Shea, President and CEO of INOVIO. &#147;To achieve these goals, INOVIO must strategically prioritize
our resources to capitalize on its demonstrated ability to generate functional <FONT STYLE="white-space:nowrap">T-cell</FONT> and antibody immune responses, lack of anti-vector response, tolerability for
<FONT STYLE="white-space:nowrap">re-administration</FONT> and favorable temperature stability for transport, storage and distribution.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>First Quarter Program Updates </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19:</FONT> INNOVATE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO has decided to prioritize its <FONT STYLE="white-space:nowrap">COVID-19</FONT> efforts to advance its heterologous booster strategy. In so doing, the
company will discontinue its Phase 3 INNOVATE trial. This decision reflects emerging global data that indicate a lower incidence of severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> cases<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>,
which would necessitate an increase in trial size and costs for INNOVATE. In contrast, the heterologous booster market offers greater opportunities as the world prepares to enter the endemic phase of <FONT STYLE="white-space:nowrap">COVID-19.</FONT>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19:</FONT> Heterologous Booster &#150; Preliminary Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With its partner, Advaccine, INOVIO reported positive T cell immune response data with <FONT STYLE="white-space:nowrap">INO-4800</FONT> as a heterologous
booster to an inactivated <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine. This data came from a heterologous booster clinical trial conducted by Advaccine that assessed the immune responses following a primary series of two doses of an
inactivated <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine followed by a booster with <FONT STYLE="white-space:nowrap">INO-4800</FONT> after 3 or 6 months.&nbsp;Interim immunogenicity data showed that using
<FONT STYLE="white-space:nowrap">INO-4800</FONT> as a booster after 6 months resulted in a <FONT STYLE="white-space:nowrap">6.3-fold</FONT> increase in T cell immune response. In a separate Advaccine study where a third dose of an inactivated <FONT
STYLE="white-space:nowrap">COVID-19</FONT> vaccine was assessed, the cellular response increased by <FONT STYLE="white-space:nowrap">1.7-fold.</FONT> The highest booster effect of <FONT STYLE="white-space:nowrap">INO-4800</FONT> was observed with a
2 mg dose of <FONT STYLE="white-space:nowrap">INO-4800</FONT> delivered 6 months after a primary series with an inactivated vaccine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following <FONT
STYLE="white-space:nowrap">INO-4800</FONT> vaccination, the preservation of cross-reactive T cell responses remains a consistent observation against multiple <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT>
variants of concern, including Omicron, without a significant loss in response magnitude. T cells that can recognize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> may play a role in reducing disease
severity. Therefore, <FONT STYLE="white-space:nowrap">INO-4800</FONT> has the potential to play an important role in reducing incidence of severe <FONT STYLE="white-space:nowrap">COVID-19</FONT> cases, which could reduce hospitalizations as the
virus continues to mutate and new variants arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is continuing discussions with regulators in select countries regarding potential regulatory
pathways for licensure. The Company believes the increased global awareness about the importance of T cell immune responses and durability of protection for effective booster vaccines correspond well with
<FONT STYLE="white-space:nowrap">INO-4800&#146;s</FONT> key strength &#150; its ability to generate CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cell responses against
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is planning to expand its partnership with Advaccine
beyond <FONT STYLE="white-space:nowrap">INO-4800</FONT> to include heterologous boosters and vaccine candidates covering future variants. The expanded partnership will allow both companies to share data, leverage Advaccine&#146;s multiple
manufacturing sites in China, and access opportunities globally. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">VGX-3100:</FONT> <FONT STYLE="white-space:nowrap">HPV-associated</FONT>
Cervical High-Grade Squamous Intraepithelial Lesions (HSIL) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on feedback from the U.S. Food and Drug Administration (FDA), INOVIO has changed its
development plans for <FONT STYLE="white-space:nowrap">VGX-3100</FONT> for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> cervical HSIL to a biomarker-selected population. In a recent preliminary
letter, the FDA advised INOVIO that the REVEAL2 Phase 3 study would not be sufficient to support approval of a potential marketing application for <FONT STYLE="white-space:nowrap">VGX-3100</FONT> in that population. The FDA recommended that using
REVEAL2 as an exploratory study to evaluate a biomarker-selected population and then conducting one or two additional well-controlled trials in the biomarker-positive population would be more likely to provide sufficient evidence to support approval
of a marketing application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To better assess potential efficacy in a biomarker-selected population, the Company plans to amend the fully enrolled REVEAL2
trial to revise the primary analysis population from the <FONT STYLE="white-space:nowrap">all-comers</FONT> population to the biomarker-positive population. Both the biomarker-positive population and the
<FONT STYLE="white-space:nowrap">all-comers</FONT> population will be analyzed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO will continue its REVEAL2 trial to completion and assess the path
forward for the <FONT STYLE="white-space:nowrap">VGX-3100</FONT> program following analysis of the REVEAL2 results. Given the likelihood for at least one additional trial, INOVIO no longer expects to submit a BLA in 2023 for <FONT
STYLE="white-space:nowrap">VGX-3100.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">INO-3107:</FONT> Recurrent Respiratory Papillomatosis (RRP) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO completed enrollment of 32 participants in the open-label, multicenter Phase 1/2 trial to evaluate the efficacy, safety, tolerability, and
immunogenicity of <FONT STYLE="white-space:nowrap">INO-3107</FONT> in participants with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-6/11-associated</FONT></FONT> RRP who have required at least two interventions in the past
year for the removal of associated papilloma(s). For this study, adult participants will first undergo removal of their papilloma(s) and will subsequently receive four doses of <FONT STYLE="white-space:nowrap">INO-3107,</FONT> one every three weeks.
The efficacy endpoint will be a reduction in the frequency of therapeutic interventions following the first dose of <FONT STYLE="white-space:nowrap">INO-3107</FONT> relative to the frequency prior to study therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO expects preliminary efficacy, safety and immunogenicity data from a portion of participants from this Phase 1/2 trial in the second half of this year.
The Company will share additional clinical development plans after analysis of the data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">INO-5401:</FONT> Newly
Diagnosed Glioblastoma Multiforme (GBM) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s abstract providing <FONT STYLE="white-space:nowrap">follow-up</FONT> Phase 1/2 overall survival,
safety and immunogenicity data from the Company&#146;s novel combination trial of DNA medicines <FONT STYLE="white-space:nowrap">INO-5401</FONT> and <FONT STYLE="white-space:nowrap">INO-9012</FONT> in combination with Regeneron&#146;s <FONT
STYLE="white-space:nowrap">PD-1</FONT> inhibitor Libtayo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (cemiplimab) in the treatment of newly diagnosed GBM has been selected for oral presentation as part of an Oral Abstract Session at
the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting under the title &#147;Intramuscular (IM) <FONT STYLE="white-space:nowrap">INO-5401</FONT> + <FONT STYLE="white-space:nowrap">INO-9012</FONT> with electroporation (EP) in
combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma&#148;. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The complete text of the abstract will be posted on the website, meetings.asco.org, on May&nbsp;26, 2022 at
5:00 PM EDT. The 2022 ASCO Annual Meeting will take place on June <FONT STYLE="white-space:nowrap">3-7,</FONT> 2022 at the McCormick Place Convention Center in Chicago, Illinois. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>First Quarter 2022 Financial Results </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO
reported total revenue was $199,000 for the three months ended March&nbsp;31, 2022, compared to $371,000 for the same period in 2021. Total operating expenses were $71.9&nbsp;million compared to $52.9&nbsp;million for the same period in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s net loss for the quarter ended March&nbsp;31, 2022, was $79.1&nbsp;million, or $0.36 per basic and diluted share, compared to net loss of
$54.4&nbsp;million, or $0.27 per basic and diluted share, for the quarter ended March&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development (R&amp;D) expenses for the three months ended March&nbsp;31, 2022, were $56.0&nbsp;million compared to $39.0&nbsp;million for the same
period in 2021. The increase in R&amp;D expenses was primarily related to higher drug manufacturing and clinical trial expenses related to <FONT STYLE="white-space:nowrap">INO-4800</FONT> and higher employee compensation. The increase was also due
to $6.3&nbsp;million lower contra-research and development expense recorded from grant agreements. These increases were offset by lower engineering services and expensed equipment related to our
CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> 3PSP device array automation project, among other variances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative (G&amp;A) expenses were $16.0&nbsp;million for the three months ended March&nbsp;31, 2022, versus $13.9&nbsp;million for the same period in 2021. The increase in G&amp;A expenses was primarily related to an increase in employee
compensation and insurance expenses, among other variances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2022, cash and cash equivalents and short-term investments were $360.4&nbsp;million compared to $401.3&nbsp;million as of
December&nbsp;31, 2021. As of March&nbsp;31, 2022, the Company had 226.5&nbsp;million common shares outstanding and 247.8&nbsp;million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion,
as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s balance sheet and
statement of operations are provided below. Additional information is included in INOVIO&#146;s quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022, which can be accessed at:
<U>http://ir.inovio.com/financials/default.aspx</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call / Webcast Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s management will host a live conference call and webcast at 4:30 p.m. Eastern Daylight Time today to discuss INOVIO&#146;s financial results and
provide a general business update. The live webcast and replay may be accessed by visiting INOVIO&#146;s website at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">http://ir.inovio.com/events-and-presentations/default.aspx.</FONT></FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people
with cancer and <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic
Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka
Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences,
Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit www.inovio.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Jeff Richardson, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> jeff.richardson@inovio.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Ben Matone, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> ben.matone@inovio.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Institute for Health Metrics Evaluation. Used with permission. All rights reserved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain
forward-looking statements relating to our business, including our plans to develop DNA medicines, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical studies and clinical
trials and the availability and timing of data from those studies and trials, our planned heterologous booster strategy, our ability to obtain regulatory approval for our product candidates, and our plans to expand our collaboration with Advaccine..
Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials, product development
programs and commercialization activities and outcomes, our ability to secure sufficient manufacturing capacity to mass produce our product candidates, the availability of funding to support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones
for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions
targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and
whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can
withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or
other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2021, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2022, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any
product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking
information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9pt"><B>ASSETS</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,009,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,143,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,384,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,170,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,003,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,466,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,487,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,565,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,946,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,836,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets from affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">399,906,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">448,444,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,696,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,453,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in affiliated entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,369,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,906,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,499,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,513,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,513,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,251,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,571,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,273,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,425,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">445,511,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">495,941,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9pt"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,115,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,644,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses due to affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,407,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,827,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,326,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,672,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,603,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant funding liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,283,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,559,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant funding liability from affiliated entity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Total current liabilities</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,359,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,741,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible senior notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,207,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,959,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,765,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,459,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Total liabilities</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,426,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,272,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Stockholders&#146; equity:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,642,419,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,609,589,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,287,103,438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,209,855,522</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(457,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(282,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:9pt"><B>Total Inovio Pharmaceuticals, Inc. stockholders&#146; equity</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,085,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,669,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">445,511,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">495,941,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue under collaborative research and development arrangements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue under collaborative research and development arrangements with affiliated
entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenues</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,978,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,044,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,953,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,881,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,932,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,925,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,732,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,554,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">669,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">769,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(313,488</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(513,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on investment in affiliated entities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(537,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(830,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,840,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(847,958</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153,468</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76,908,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,967,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share in net loss of Geneos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,165,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(434,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,073,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(54,402,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average number of common shares outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218,940,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,414,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d259881dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g259881g0511010559890.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Dr.&nbsp;Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; May&nbsp;10, 2022 &#150; INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to
help protect people from infectious diseases and treat people with cancer and <FONT STYLE="white-space:nowrap">HPV-associated</FONT> diseases, today announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer (CEO)
of INOVIO, effective immediately. Dr.&nbsp;Shea succeeds Dr.&nbsp;J. Joseph Kim in these roles. Dr.&nbsp;Kim has also resigned as a member of the INOVIO board of directors, and the board intends to appoint Dr.&nbsp;Shea as a director following
INOVIO&#146;s annual meeting of the stockholders on May&nbsp;16, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Simon&nbsp;X. Benito, Chairman of the Board of INOVIO, said, &#147;On
behalf of the entire Board, I am pleased to announce Dr.&nbsp;Shea&#146;s appointment as President and CEO of INOVIO. Dr.&nbsp;Shea brings more than 25 years of experience in the life sciences and biotech industries. Since joining as Chief Operating
Officer in March 2019, Dr.&nbsp;Shea has shown exceptional leadership and technical expertise overseeing INOVIO&#146;s manufacturing, commercial, business development, project and alliance management operations as well as serving as a key member of
the executive team. We look forward to Dr.&nbsp;Shea taking the helm during a particularly challenging period in INOVIO&#146;s history. Her tenured leadership, deep knowledge of our business, and broad expertise makes her an excellent choice for the
role.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Benito added, &#147;On behalf of the Board, I would like to thank Dr.&nbsp;Kim for his commitment to INOVIO and his founding vision
of a world free from disease through DNA medicines. As a <FONT STYLE="white-space:nowrap">co-founder</FONT> of the Company, Joseph has been a true entrepreneur and pioneer in the field of vaccines and immunotherapies since its inception. I am
pleased that he has agreed to act in an advisory capacity to Dr.&nbsp;Shea during the transition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Shea said, &#147;I am honored to take on
the role of CEO and grateful for the support of the Board in entrusting me to lead INOVIO for its next chapter. While we have many challenges to face, I believe strongly in the potential of our DNA medicines technology and continue to be inspired by
INOVIO&#146;s talented and dedicated team. I look forward to reshaping the future of INOVIO and advancing our efforts across multiple therapeutic areas with the potential to improve the lives of patients globally.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to joining INOVIO in March 2019, Dr.&nbsp;Shea served as the Chief Operating Officer and later the Chief Executive Officer of Aeras, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> organization dedicated to developing new vaccines against tuberculosis (TB). During her tenure she oversaw two major clinical trial breakthroughs in the
development of TB vaccines. Previously, she held executive roles at Emergent BioSolutions and was also the General Manager and Vice President of The Oxford- Emergent Tuberculosis Consortium. A molecular biologist and cell cycle geneticist,
Dr.&nbsp;Shea received a BSc Hons in Applied Biology from the University of Bath and holds a Ph.D. from the National Institute for Medical Research in the United Kingdom. She has been named as an inventor on more than 20 patents, has authored
numerous publications, served on multiple advisory boards and currently serves on the board of Trustees for the Sabin Vaccine Institute. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to potentially treat and protect people from infectious diseases,
cancer, and diseases associated with HPV. Our DNA medicines are delivered using our proprietary smart device to produce a robust and tolerable immune response against targeted pathogens and cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic
Preparedness Innovations, Defense Advanced Research Projects Agency/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense/Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka
Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences,
Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit <U>www.inovio.com</U><U>.</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONTACTS: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors:</B> Ben Matone, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> <U>ben.matone@inovio.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media:</B> Jeff Richardson, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ino-20220509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 5/11/2022 12:25:22 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:ino="http://www.inovio.com/20220509"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.inovio.com/20220509"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20220509_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20220509_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ino-20220509_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 5/11/2022 12:25:22 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ino-20220509_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 5/11/2022 12:25:23 AM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ino-20220509.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g259881g0510123631217.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g259881g0510123631217.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( -X# 2(  A$! Q$!_\0
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MA /44M%8FQQ6KPQQ^*W62-55K96AX"@\D-S@G/3H,\U>\.2VUOJ$^G6R"/\
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MWW^CS^A/ R?S'Y5W=<+\2?N:(!]_[:,?I7=4 <-XB_Y*7X<_W&_]FK5\>_\
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M55)+<Y^9TV[['JM5KV_MM/A\VYE6-2<+GJQ] .]<?%>^()LS/J,23<XB6/\
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;D,S0RJ9+K>N-C!0!M!^;)R<@8[UV5%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g259881g0511010559890.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g259881g0511010559890.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< 0\# 2(  A$! Q$!_\0
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M9HH%#2R*@)"@L<9)Z"J9UW2@2#J%OD'!^<5C1WG]NSZ2I'$4374X]'7Y0/\
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/'0G Y(K6HH 6BDHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140614022771464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d259881d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20220509.xsd" xlink:type="simple"/>
    <context id="duration_2022-05-09_to_2022-05-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2022-05-09_to_2022-05-09">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-05-09_to_2022-05-09"
      id="Hidden_dei_EntityCentralIndexKey">0001055726</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-05-09_to_2022-05-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-05-09_to_2022-05-09">2022-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2022-05-09_to_2022-05-09">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-05-09_to_2022-05-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-05-09_to_2022-05-09">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-05-09_to_2022-05-09">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-05-09_to_2022-05-09">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2022-05-09_to_2022-05-09">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-05-09_to_2022-05-09">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-05-09_to_2022-05-09">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-05-09_to_2022-05-09">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-05-09_to_2022-05-09">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-05-09_to_2022-05-09">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-05-09_to_2022-05-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-05-09_to_2022-05-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-05-09_to_2022-05-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-05-09_to_2022-05-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-05-09_to_2022-05-09">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-05-09_to_2022-05-09">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-05-09_to_2022-05-09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-05-09_to_2022-05-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ J8.J5)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " "I@ZI4IK'/W^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "I@ZI4F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( *F#JE0X=1&#500  .D0   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "I@ZI4GZ ;\+$"  #B#
M#0              @ &8#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *F#
MJE27BKL<P    !,"   +              "  70/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( *F#JE0<.&7J/P$  #P"   /              "  5T0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "I@ZI4)!Z;HJT   #X 0  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "I@ZI499!YDAD!  #/ P  $P              @ &N$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #X$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d259881d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d259881d8k.htm">d259881d8k.htm</File>
    <File>d259881dex991.htm</File>
    <File>d259881dex992.htm</File>
    <File>ino-20220509.xsd</File>
    <File>ino-20220509_lab.xml</File>
    <File>ino-20220509_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d259881d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d259881d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20220509_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20220509_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20220509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20220509",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d259881d8k.htm",
      "contextRef": "duration_2022-05-09_to_2022-05-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d259881d8k.htm",
      "contextRef": "duration_2022-05-09_to_2022-05-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.inovio.com//20220509/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-22-146350-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-146350-xbrl.zip
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M][D6:7,9A(76\/E:AG4W'"'YK>9VLY,1H649"="MT_CC\Z<+=RA&O"8#'?/
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M(Z6%3JDPE2YB)NJDD1-DFM)(:@ENEG;XUN5" 33WA;FA09L0>VJ:V<9JRG^
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M-Z)I^#&I^)FR]1"&T_5"YCY\9:0F5!#J!W3K5R1MX]1$X7-+DZ7F25.JJ67
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MM82YLT[K5+PC_#,HL5#ZWC)V"9KV[+:H,4/&#^6+-J:J,])B<9048V-MAJU
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M.Z0=*WH/?##>C5BPCR)@5AU20B/;G4SC4"*?0X+ '/!/5V^?@ZV-4ER@E'=
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ME;;@,+06@,*,K6FRX4:1MB_1WKQF"1C@7_D,C*@M%B=9E3XE##G2TDE,!&(
M<A2\9H*:%&C9XY;!O'6(GP8\(+!.#R+YRB2?&_-PB%XO6<BNTQ6>!/]<12;C
ML)D._:CSG(II[33P:[!Y*:K).\@#RFY0YZM.<;%.4D'27I0$&^!)'<B.4Z%*
M?J.<B"5Z$E+J^H$:" .V,/B*50DZ'!?CY8>8H-,EO %05)NP:$@NBLL<M.HK
MNC#_K5R8F\).R[(EUKT"RQ?G>/[Y8(K)= ^AAO[/SS$>;\H:ET-GK"";6!]@
M%XN)OTS8;UZZP Q*#"_VW12V;M1L(6Q0ML$2^Q'%H6*>5H!7BT;G8&;)F!A
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M5" ^V0W54[E8&1S!QI$XU:(]2QM5MJO*7 O!;6>G%T_A_0"/AVSM08"E&7P
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MD'E)V846>X]Z^<EC:Q3,1L,H/5E+QT=74-1,P[2RGF4;R;V9?-O@^J\-LO%
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M<7.I<Q'&<'#RW1WLWEY]O)Z^GXW9]6@TF]Q<(O(]]N,/QR_;Y^R:;[RKQ^V
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MIBQR#F#QC,/CL$BX2<"\@%,BU))>4>(TU>23",02A61 (V/8@WHM#/"U"VD
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M4$L! A0#%     @ J8.J5!CV&"Z1)@  2$$! !$              ( !@AD
M &0R-3DX.#%D97@Y.3$N:'1M4$L! A0#%     @ J8.J5-4EK.'^"@  L1P
M !$              ( !0D   &0R-3DX.#%D97@Y.3(N:'1M4$L! A0#%
M  @ J8.J5&B[%0Q  P  2PL  !               ( !;TL  &EN;RTR,#(R
M,#4P.2YX<V102P$"% ,4    " "I@ZI4FF&+Y7D&  "[1@  %
M    @ '=3@  :6YO+3(P,C(P-3 Y7VQA8BYX;6Q02P$"% ,4    " "I@ZI4
M8+C^J+X$   \+   %               @ &(50  :6YO+3(P,C(P-3 Y7W!R
;92YX;6Q02P4&      8 !@!\ 0  >%H

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
